On May 4, Nathaniel Hogrebe, PhD; Matthew Ishahak, PhD; and Jeffrey Millman, PhD had their review titled “Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes,” published in Cell Stem Cell. In diabetes treatment, there is great potential for islet-like endocrine clusters from human pluripotent stem cells (hPSCs) to provide a limitless […]
Dr. Jeffrey Millman has received a renewal of his NIH R01 grant titled “Studying the Role of the Microenvironment on Differentiation and Maturation of Beta Cells”, providing 4 years of additional support into his research. Human pluripotent stem cells (hPSCs) hold great potential as a renewable source of insulin-producing islets for diabetes treatment. While transplantation […]
On May 2, Punn Augsornworawat, PhD received the Biomedical Engineering Outstanding Research Award for his work in the single-cell sequencing of stem cell-derived islets for diabetes cell therapy. Augsornworawat joined the Millman Lab back in 2018 as a doctoral student in the Biomedical Engineering PhD program. His interests lie in using bioinformatics to study islet development […]
On March 16, Jeffrey R. Millman, PhD and collaborators had their research titled “Differential Function and Maturation of Human Stem Cell-Derived Islets After Transplantation,” published in issue 3 of “Stem Cells Translational Medicine.” It is evident that cell replacement therapy is a potential treatment for patients with diabetes. One possible renewable source of replacement cells are stem-cell […]
On April 1, ReachMD released an interview featuring Alexis McKee, MD in their “Diabetes Discourse” series. The discussion is titled, “Collaborative Goal Setting in Type 2 Diabetes: Tailoring Treatment Plans for Patients.” In the 10-minute interview, McKee discusses communication strategies that can be used to create personalized treatment plans and to improve adherence among patients […]
Kim A. Carmichael, MD published a recent article in the February 2022 issue of Consultant 360 titled, “What Do You Need to Know About GLP-1 Receptors Agonists?” GLP-1 agonists, otherwise known as glucagon-like peptide 1 agonists, are an important class of medications for patients diagnosed with type 2 diabetes. As the author and series editor, […]